BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹722.70
- Market cap
- ₹11,375 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.0×Sector 46.1×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other board meeting date announcements
All →Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.
EPL Board Meeting Date
EPL will hold a board meeting on November 4, 2026 to consider September quarter results. Trading window re-opens 48 hours after results are declared.